It's been months. You haven't recovered. You are not imagining this.

There's significant overlap, and a meaningful percentage of Long COVID patients meet diagnostic criteria for ME/CFS — particularly those whose dominant symptoms are fatigue and post-exertional malaise (PEM). Studies from groups including the Bateman Horne Center suggest roughly half of Long COVID patients with persistent symptoms at 6+ months meet ME/CFS criteria. Evidence level: Strong for the overlap, still evolving on whether they're the same underlying disease or related ones.

Why it matters clinically: if you have PEM (symptoms worsening 12–48 hours after physical, cognitive, or emotional exertion), the ME/CFS treatment framework is more useful than a generic "rehab" framework. Pacing matters. Graded exercise therapy can be actively harmful. If you also have orthostatic intolerance, mast cell symptoms, or small fiber neuropathy, you're describing a phenotype that's been studied for decades under the ME/CFS umbrella. Bringing this language to your doctor often unlocks better care.

Pacing is staying within your current energy envelope to avoid post-exertional crashes. It's the single most evidence-supported intervention for people with PEM-dominant Long COVID or ME/CFS. The idea: every crash sets you back further, so the goal is to stop crashing — even if that means doing dramatically less than feels reasonable.

In practice, pacing involves heart rate monitoring (a chest strap or wearable, with an anaerobic threshold roughly calculated as 0.6 × (220 − age) for many patients), scheduled rest before you feel tired, breaking activities into small blocks, and treating cognitive and emotional exertion as real energy expenditure. Apps like Visible and Bearable are built specifically for this. It's slow and frustrating — but for many patients, months of strict pacing creates the stable baseline that other interventions (LDN, treating dysautonomia, addressing mast cell) can build on. Pushing through is not bravery in this illness; it's how people get worse.

Low-dose naltrexone (LDN) is one of the more promising medications under investigation. It's been used for years in ME/CFS, fibromyalgia, and autoimmune conditions, and has moved into Long COVID research because of overlapping mechanisms — neuroinflammation and glial cell activation. Several small studies and case series have reported reduced fatigue, improved cognition, and reduced pain at doses of 1.5–4.5 mg. Evidence level: Emerging, with several active trials.

LDN is generally well-tolerated. Most people start at 0.5 or 1.5 mg and titrate up over weeks. Side effects, when they occur, are usually vivid dreams or temporary sleep disturbance. Compounding pharmacies make the low-dose form (the standard 50 mg naltrexone tablet is too high for this purpose). Most US PCPs won't prescribe it because it's off-label, but Long COVID clinics, functional medicine doctors, and some pain specialists will. It's not a miracle drug — many patients see partial benefit, some see none — but the risk-benefit profile is favorable enough that it's reasonable to ask about.

There's a real signal here that's gotten distorted by wellness marketing. Long COVID involves measurable autonomic dysfunction in many patients — heart rate variability is reduced, vagal tone is impaired, and the sympathetic nervous system is often stuck "on." Interventions that genuinely shift autonomic state — slow breathing (4–6 breaths/min), cold exposure within tolerance, gentle yoga nidra, and in some studies, transcutaneous vagus nerve stimulation devices — have small but real evidence behind them. Evidence level: Emerging.

What to be skeptical of: programs marketed as "brain retraining" that promise full recovery (DNRS, Gupta, Lightning Process) charge hundreds to thousands of dollars and have no controlled trial evidence in Long COVID. Some patients report benefit; others report being blamed for not recovering. Nervous system regulation is a reasonable adjunct to medical care for some patients — particularly those with strong dysautonomia or anxiety overlap — but it is not a treatment for the underlying biology, and you do not have Long COVID because you failed to regulate your nervous system.

The honest answer is that no supplement has strong evidence in Long COVID specifically — most data is extrapolated from related conditions or based on small open-label studies. That said, a few are reasonable to consider with your doctor: low-dose nicotine patches (small studies and large patient surveys, mechanism uncertain), nattokinase and serrapeptase (popular for microclot hypotheses, weak clinical evidence), CoQ10 (some ME/CFS data), and basic deficiency correction — vitamin D, B12, ferritin, omega-3.

Be more cautious about: expensive proprietary blends, IV nutrient drips marketed for Long COVID, peptide protocols (BPC-157, thymosin alpha) which lack human trials, and anti-parasitic protocols making the rounds online. The Long COVID supplement market is essentially unregulated and patient-driven; some things in it may turn out to matter, but most are guesses. If you're going to try something, try one thing at a time, give it a fair trial (usually 6–8 weeks), and track symptoms carefully.

Yes — particularly if you've had symptoms for more than 3 months, you've been dismissed by general practitioners, or you have multi-system involvement (heart racing on standing, GI changes, neurological symptoms, MCAS-type reactions). A specialised Long COVID clinic is more likely to know the current literature, have relationships with specialists who take this seriously (cardiology for POTS, allergy/immunology for mast cell, neurology for small fiber neuropathy), and offer access to clinical trials.

The reality is that most Long COVID clinics have months-long waitlists, and the quality varies enormously — some are essentially rebranded fatigue clinics, others are genuinely research-active. Worth asking when you call: do they have a multidisciplinary team? Do they test for POTS, MCAS, small fiber neuropathy, and microclots if relevant? Do they prescribe LDN? In the meantime, a PCP willing to read the literature and order broader testing is often more useful than a specialist who only knows one organ system. Nalura can help you research the right questions to bring to either.